Popular drugs for diabetes and weight loss could have an unexpected side effect. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked ...

November is Diabetes-related Eye Disease Awareness Month, and early detection and treatment of diabetes are key to reduce the risk for significant vision loss and blindness, according to Prevent ...

Headlines warning about “Ozempic blindness” may be frightening to the millions of people taking a GLP-1 drug to treat Type 2 diabetes or for weight loss. It's not an official diagnosis, but an ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel ...

(NAPSI)—For the nearly 40 million Americans living with diabetes, the threat to their vision unfolds quietly, often without warning. Diabetic retinopathy, a complication that damages blood vessels in ...

Type 2 diabetes is among the top causes of vision loss and blindness across the world. According to studies, visual impairment due to diabetic retinopathy has increased significantly in the last 20 ...

Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...

Please provide your email address to receive an email when new articles are posted on . The odds of developing dry eye disease were nearly four-times higher in patients with moderate to severe ...

Roughly half of Americans have prediabetes or diabetes, including an increasing number of children. High blood levels of ...